|
|
Article: Aceon Gets Broader Label, Paves Sales Path For Ranexa.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
The FDA approved a wider label for Aceon (perindopril erbumine), a cardiovascular drug marketed in part by CV Therapeutics Inc. through a partnership that has laid the groundwork for eventual sales of another of its drugs, Ranexa.
"The expansion significantly increases the potential market opportunity for Aceon," John Bluth, the company's senior director of corporate communications, told BioWorld Today. "The prospect of the expanded label was certainly very attractive to us when we entered this co-promotion agreement."
Aceon's new indication is for treating patients with stable coronary artery disease to reduce the risk of ...